Business Context and Reporting Period
Company: GRI Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 5, 2025
Reporting Period: Event date of May 5, 2025
The Company, an emerging growth company incorporated in Delaware, filed this report to disclose an update to its At The Market (ATM) equity offering program.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or margin data. The only financial figures disclosed relate to the equity offering program:
- Additional Shares Authorized for Sale: Up to an aggregate gross sales price of $1,670,956.
- Shares Previously Sold: Approximately $3,604,683 in aggregate gross sales price sold to date under the Sales Agreement dated May 20, 2024.
- Total Program Capacity: Approximately $5,275,639 (sum of previously sold and newly authorized amounts).
Material Changes
The material change reported is the amendment of the At The Market Offering Agreement with H.C. Wainwright & Co., LLC. The Company filed a prospectus supplement to increase the maximum number of common shares issuable under the agreement by an additional $1,670,956.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates the Company is continuing its capital raising efforts through the existing ATM facility. No specific operational guidance or future earnings outlook is provided in this document.
Risks and Contingencies: The filing references the legality of the issuance and sale of shares, supported by an opinion from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. No specific risk factors or contingencies are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the current share price to estimate the number of shares included in the $1,670,956 authorization increase.
- Review the full Prospectus Supplement (referenced in Item 8.01) for specific terms of the offering.
- Check recent 10-Q or 10-K filings for the Company's current cash position and burn rate to assess the necessity of this capital raise.
- Confirm the total number of shares outstanding post-issuance to evaluate potential dilution.